---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-174006"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2023-06-26T23:59:59+00:00"
generated_at: "2026-06-13T17:08:04.105186+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics signs $200M ATM equity distribution agreement with Jefferies

## Summary
- New Sales Agreement with Jefferies allows issuance of up to $200M in common stock at 3.0% commission rate.
- Prior Cantor Fitzgerald ATM terminated; had raised $1.4M of its $75M capacity before termination.
- Proceeds to fund R&D for ELVN-001, ELVN-002, other preclinical programs, and general corporate purposes.
- Registration Statement (S-3) filed but not yet effective; no sales may occur until declared effective by SEC.

## SEC filing metadata
- accession: 0001193125-23-174006
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2023-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312523174006/0001193125-23-174006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312523174006/d518523d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-174006
- JSON: https://secwatch.observer/filing/0001193125-23-174006.json
- Plain text: https://secwatch.observer/filing/0001193125-23-174006.txt

## Key facts
- Material Agreements
  Enliven Therapeutics, Inc. terminated Controlled Equity Offering SM Sales Agreement (the "Prior Sales Agreement") with Cantor Fitzgerald & Co. (effective 2023-06-23).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Cantor Fitzgerald & Co.
  - Effective: 2023-06-23
  source text: On June 23, 2023, the Company delivered written notice to Cantor Fitzgerald to terminate the Prior Sales Agreement pursuant to Section 12(b) thereof, effective as of June 23, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523174006/0001193125-23-174006-index.htm
- Material Agreements
  Enliven Therapeutics, Inc. entered into Open Market Sale Agreement SM (the "Sales Agreement") with Jefferies LLC valued at up to $200.0 million (effective 2023-06-23).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Value: up to $200.0 million
  - Effective: 2023-06-23
  source text: On June 23, 2023, Enliven Therapeutics, Inc. (the "Company") entered into an Open Market Sale Agreement SM (the "Sales Agreement") with Jefferies LLC as the Company's sales agent (the "Agent"), pursuant to which the Company may offer and sell shares (the "Shares") of its common stock, par value $0.001 per share ("Common Stock") from time to time through the Agent, in such share amounts as the Company may specify by notice to the Agent, in accordance with the terms and conditions set forth in the Sales Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1672619/000119312523174006/0001193125-23-174006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.